Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Licensing deals
Biotech
Amicus pays Dimerix $30M for late-phase rare kidney disease drug
Amicus has bagged U.S. rights to the phase 3 prospect DMX-200, establishing it as a challenger to Travere Therapeutics in a rare kidney disease.
Nick Paul Taylor
May 1, 2025 10:59am
Ferrer nabs European rights for ALS asset in €500M pact
Apr 28, 2025 2:40pm
Mosaic licenses 2 clinical stage tumor drugs from Otsuka's Astex
Apr 24, 2025 10:00am
Boehringer slots synthetic lethal program into oncology pipeline
Apr 23, 2025 7:45am
Sanofi hands cancer drug to Innate as it pivots R&D pact focus
Apr 23, 2025 6:35am
Stealth biotech bags rights to VelaVigo bispecific in $440M deal
Apr 18, 2025 7:40am
